Acadia to Move Experimental Pediatric Rett Syndrome Drug to Phase 3

San Diego Biotechnology Network
San Diego Biotechnology Network
Acadia to Move Experimental Pediatric Rett Syndrome Drug to Phase 3
Loading
/

Acadia Pharmaceuticals said it plans to advance a drug it licensed last year from Australia?s Neuren Pharmaceuticals into a late-stage trial following promising Phase 2 results of the potential Rett syndrome treatment. San Diego-based Acadia (NASDAQ: ACAD) announced in August that it had licensed the drug, trofinetide, for development and commercialization in North America as [?]


ADVERTISEMENT — Advertise With Biotech Networks